|1.||Masuda, Noriyuki: 9 articles (08/2015 - 06/2005)|
|2.||Kudoh, Shinzoh: 8 articles (04/2014 - 06/2002)|
|3.||Igawa, Satoshi: 7 articles (08/2015 - 08/2007)|
|4.||Yamamoto, Nobuyuki: 7 articles (06/2015 - 08/2007)|
|5.||Kimura, Tatsuo: 7 articles (04/2014 - 06/2002)|
|6.||Fukuoka, Masahiro: 7 articles (03/2014 - 08/2005)|
|7.||Yamamoto, Noboru: 6 articles (10/2015 - 03/2010)|
|8.||Ohe, Yuichiro: 6 articles (10/2015 - 09/2010)|
|9.||Yokoba, Masanori: 6 articles (08/2015 - 06/2005)|
|10.||Takakura, Akira: 6 articles (08/2015 - 01/2009)|
|1.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/01/2009 - "In Japan, amrubicin is considered an effective agent for relapsed small cell lung cancer. "
03/01/2006 - "[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin]."
05/01/2014 - "Amrubicin (AMR), a new anthracycline agent, has shown promising results for advanced small-cell lung cancer (SCLC), although the efficacy of AMR alone against refractory relapsed SCLC is insufficient. "
08/01/2009 - "Amrubicin is a new anticancer drug that has been shown to exert efficacy against small cell lung cancer. "
05/01/2011 - "Recent reports have suggested the efficacy of amrubicin (AMR) for relapsed small-cell lung cancer (SCLC). "
01/01/1989 - "Compared with ADR, SM-5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric). "
04/01/2012 - "Therefore, amrubicin may be useful in the treatment of anthracycline-refractory or anthracycline-resistant tumors."
01/01/1989 - "When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100-300 mm3, SM-5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM-5887, and 7 of them were strongly suppressed in their growth by SM-5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection. "
04/01/2012 - "Amrubicin activity was assessed in multi-drug-resistant cell lines and human tumor explants using cytotoxicity assays, confocal microscopy, fluorescence time-lapse imaging, flow cytometry, immunoblotting, and gene expression profiling techniques. "
04/01/2012 - "Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells."
|3.||Lung Neoplasms (Lung Cancer)
03/01/2014 - "The combination of EGFR-TKI and amrubicin may be a promising treatment for lung cancer with wild-type EGFR and K-ras mutation. "
05/01/2012 - "Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial."
07/01/2010 - "A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer."
01/01/2010 - "Further studies are needed to investigate the benefit of amrubicin monotherapy among elderly patients with previously treated lung cancer."
01/01/2010 - "The present study evaluates the toxicity and effect of amrubicin especially in elderly patients with previously treated lung cancer. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2010 - "Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401)."
08/01/2007 - "We conducted a multicenter phase II study of amrubicin, a novel 9-aminoanthracycline, to evaluate its efficacy and safety in patients with non-small-cell lung cancer (NSCLC). "
08/01/2007 - "Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study."
03/01/2006 - "This multicenter phase II study was conducted to evaluate the efficacy and safety of amrubicin in patients with non-small-cell lung cancer (NSCLC). "
03/01/2006 - "Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial."
07/01/2011 - "Amrubicin was potentially active against previously treated large-cell neuroendocrine carcinoma."
07/01/2011 - "From January 2002 to December 2009, 18 patients with previously treated advanced large-cell neuroendocrine carcinoma received amrubicin monotherapy. "
07/01/2011 - "Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung."
04/01/1996 - "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]."
07/01/2011 - "Amrubicin is active for both small cell and non-small cell lung cancers, but its activity for large-cell neuroendocrine carcinoma is still unknown. "
|6.||Etoposide (VP 16)
|9.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Renal Dialysis (Hemodialysis)